Prothena Corporation plc — Q2 2023 Form 10-Q Summary
Business context and reporting period
Prothena is an Irish late-stage clinical biotechnology company focused on protein dysregulation and investigational therapies for neurodegenerative and rare amyloid diseases. The filing covers the three and six months ended June 30, 2023, with comparative periods ended June 30, 2022. Its principal programs include birtamimab, PRX012, PRX123, PRX005, prasinezumab and partnered or milestone-based programs with Roche, Bristol Myers Squibb (BMS) and Novo Nordisk.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Total revenue | $4.0 million | $1.3 million | $6.2 million | $2.5 million |
| Research and development | $56.0 million | $31.6 million | $100.8 million | $58.8 million |
| General and administrative | $14.5 million | $13.0 million | $28.3 million | $24.8 million |
| Loss from operations | $(66.5) million | $(43.2) million | $(122.8) million | $(81.2) million |
| Net loss | $(54.6) million | $(41.2) million | $(101.5) million | $(77.5) million |
| Net loss per share | $(1.03) | $(0.88) | $(1.92) | $(1.66) |
| Operating cash flow | Not separately provided | Not separately provided | $(92.4) million | $(72.7) million |
Revenue consisted primarily of collaboration revenue from BMS for PRX005 development services. The company had no product sales. Revenue growth did not offset substantially higher clinical development spending; the implied net loss margin was approximately negative 1,358% for Q2 and negative 1,639% for the first six months.
At June 30, 2023, cash and cash equivalents were $659.1 million, compared with $710.4 million at December 31, 2022. Cash, cash equivalents and restricted cash totaled $661.3 million. Working capital was $605.5 million, versus $669.0 million at year-end 2022. Management believes existing cash is sufficient to fund obligations for at least the next twelve months, but expects additional capital will be required for longer-term development and potential commercialization.
The filing does not disclose outstanding borrowings or conventional debt. Total liabilities were $139.0 million, including $92.5 million of deferred revenue, $3.4 million of current lease liabilities and other operating liabilities. Shareholders’ equity was $581.7 million, and accumulated deficit was $934.5 million.
Material changes versus the prior comparable period
- Q2 collaboration revenue increased 206% to $4.0 million; six-month revenue increased 151% to $6.2 million.
- Q2 R&D expense increased 77% to $56.0 million; six-month R&D expense increased 71% to $100.8 million. Increases primarily reflected higher clinical trial, personnel, consulting and manufacturing costs, particularly for PRX012 and birtamimab.
- Q2 G&A expense increased 12%; six-month G&A expense increased 14%, primarily due to higher personnel-related costs and share-based compensation.
- Interest income increased to $7.7 million in Q2 and $14.4 million for the first six months, driven by higher interest rates and cash balances.
- Net cash used in operating activities increased to $92.4 million for the first six months from $72.7 million in the prior-year period.
- Financing activities provided $41.9 million, including $20.7 million from the partial exercise of the December 2022 offering option, $18.2 million from stock-option exercises and $3.0 million from the at-the-market program.
- Shares outstanding increased to 53.5 million at June 30, 2023, from 52.1 million at December 31, 2022, reflecting equity issuance and option exercises.
Guidance, outlook, commentary, risks and unusual items
- The company expects full-year 2023 R&D and G&A expenses to increase from 2022 levels, primarily because of higher personnel, share-based compensation, clinical-trial and manufacturing costs.
- Management expects full-year 2023 net cash used in operating and investing activities of approximately $148 million to $161 million.
- Topline data from the Phase 3 AFFIRM-AL study of birtamimab and Roche’s Phase 2b PADOVA study of prasinezumab are expected in 2024. The company reported favorable post hoc VITAL results for birtamimab in Mayo Stage IV AL amyloidosis, but AFFIRM-AL remains the confirmatory registration-enabling study.
- In June 2023, BMS exercised global rights for PRX005. The definitive global license agreement was entered into on July 5, 2023, and the $55.0 million exercise payment was received in August 2023. Prothena may also receive up to $562.5 million in regulatory and sales milestones plus tiered royalties for the program.
- Novo Nordisk is conducting a Phase 2 study of NNC6019 in ATTR cardiomyopathy, with topline data expected in 2024. Prothena is eligible for additional development and sales milestones, but none were recognized in the first six months of 2023.
- Material commitments included $18.2 million of operating lease payments, $15.6 million of purchase obligations and $0.4 million of license-related contractual obligations. A Brisbane facility sublease represents approximately $14.9 million of future payments and had not commenced for accounting purposes at June 30, 2023.
- The company remains loss-making and dependent on future financing, collaboration payments, royalties and milestones. Clinical development, regulatory approval, manufacturing, intellectual-property protection, reliance on third parties and collaborator performance remain significant risks.
- The company reported no material legal proceedings, no off-balance-sheet arrangements and effective disclosure controls as of June 30, 2023.
Most important facts for investors to verify
- Verify the timing, design, enrollment and results of the AFFIRM-AL and PADOVA studies, including whether expected 2024 data support further development or regulatory filings.
- Verify completion and accounting treatment of the BMS global PRX005 license and the receipt of the $55.0 million payment in August 2023.
- Assess cash runway against the disclosed 2023 cash-use guidance and the company’s stated need for additional capital.
- Review the sensitivity of future revenue to uncertain BMS, Roche and Novo Nordisk milestones, royalties and collaborator decisions.
- Monitor R&D spending, clinical-trial costs, manufacturing commitments and the unrecognized Brisbane lease obligations.
- Evaluate dilution risk from the at-the-market program, future equity financing and approximately 9.9 million outstanding stock options.
- Confirm that positive post hoc VITAL findings are not treated as equivalent to confirmatory Phase 3 evidence or regulatory approval.